Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4794-4800

  Brinch, Karoline Sidelmann ^a   Frimodt Møller, Niels ^b   Høiby, Niels ^c   Kristensen, Hans Henrik ^a  

^a NOVOZYMES A S   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; FREUND ADJUVANT; PLECTASIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COUNT; BIOASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; MOUSE; NONHUMAN; PERITONITIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; FEMALE; HALF-LIFE; IMMUNIZATION; MICE; PEPTIDES; PERITONITIS; PNEUMOCOCCAL INFECTIONS;

EID: 70350310339     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00440-09     Document Type: Article

References (33)

1. Bugelski, P. J., and G. Treacy. 2004. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6:10-16.
2. Christie, D. J., N. Vanburen, S. S. Lennon, and J. L. Putnam. 1990. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 75:518-523.
3. Climo, M. W., R. L. Patron, B. P. Goldstein, and G. L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42:1355-1360.
4. Dajcs, J. J., B. A. Thibodeaux, D. O. Girgis, M. D. Shaffer, S. M. Delvisco, and R. J. O'Callaghan. 2002. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Investig. Ophthalmol. Vis. Sci. 43:3712-3716.
5. Fischer, R. L., S. Buskov, H. H. Kristensen, and N. Frimodt-Moller. 2006. Plectasin, a new antimicrobial peptide: activity in vivo in mice against gram-positive cocci, abstr. F-1219. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
6. Freedman, M. S., and A. R. Pachner. 2007. Neutralizing antibodies to biological therapies: a "touch of gray" vs a "black and white" story. Neurology 69:1386-1387.
7. Frimodt-Moller, N. 1993. The mouse peritonitis model: present and future use. J. Antimicrob. Chemother. 31(Suppl. D):55-60.
8. Geng, D., G. Shankar, A. Schantz, M. Rajadhyaksha, H. Davis, and C. Wagner. 2005. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J. Pharm. Biomed. Anal. 39:364-375.
9. Gordon, Y. J., E. G. Romanowski, and A. M. McDermott. 2005. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30:505-515.
10. Haller, C. A., M. E. Cosenza, and J. T. Sullivan. 2008. Safety issues specific to clinical development of protein therapeutics. Clin. Pharmacol. Ther. 84:624-627.
11. Hancock, R. E., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
12. Jado, I., R. Lopez, E. Garcia, A. Fenoll, J. Casal, and P. Garcia. 2003. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52:967-973.
13. Johnsona, D. M., M. G. Stilwella, T. R. Fritschea, and R. N. Jonesab. 2006. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn. Microbiol. Infect. Dis. 56:69-74.
14. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. (Pubitemid 47598444)
15. Knudsen, J. D., N. Frimodt-Moller, and F. Espersen. 1995. Experimental Streptococcus pneumoniae infection in mice for studying correlation of in-vitro and in-vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob. Agents Chemother. 39:1253-1258.
16. Koren, E., L. A. Zuckerman, and A. R. Mire-Sluis. 2002. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360.
17. Marr, A. K., W. J. Gooderham, and R. E. Hancock. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6:468-472.
18. Mire-Sluis, A. R. 2002. Challenges with current technology for the detection, measurement and characterization of antibodies against biological therapeutics. Dev. Biol. (Basel) 109:59-69.
19. Mire-Sluis, A. R., Y. C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, E. Shores, S. J. Swanson, G. Taniguchi, D. Wierda, and L. A. Zuckerman. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289:1-16.
20. Mygind, P. H., R. L. Fischer, K. M. Schnorr, M. T. Hansen, C. P. Sonksen, S. Ludvigsen, D. Raventos, S. Buskov, B. Christensen, L. De Maria, O. Taboureau, D. Yaver, S. G. Elvig-Jorgensen, M. V. Sorensen, B. E. Christensen, S. Kjaerulff, N. Frimodt-Moller, R. I. Lehrer, M. Zasloff, and H. H. Kristensen. 2005. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437:975-980.
21. Nielsen, L. A., B. T. Ravn, J. Lichtenberg, R. L. Fischer, N. Frimodt-Moller, and H. H. Kristensen. 2007. In vivo profiling of plectasin variant NZ2114, a novel promising antimicrobial peptide, abstr. F1-1662. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
22. Pachner, A. R., D. Dail, E. Pak, and K. Narayan. 2005. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J. Neuroimmunol. 166:180-188.
23. Rudick, R. A., N. A. Simonian, J. A. Alam, M. Campion, J. O. Scaramucci, W. Jones, M. E. Coats, D. E. Goodkin, B. Weinstock-Guttman, R. M. Herndon, M. K. Mass, J. R. Richert, A. M. Salazar, F. E. Munschauer III, D. L. Cookfair, J. H. Simon, L. D. Jacobs, et al. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272. (Pubitemid 28240338)
24. Schellekens, H. 2003. The immunogenicity of biopharmaceuticals. Neurology 61:S11-S12.
25. Schellekens, H. 2002. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24:1720-1740.
26. Shankar, G., C. Pendley, and K. E. Stein. 2007. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25:555-561.
27. Shankar, G., E. Shores, C. Wagner, and A. Mire-Sluis. 2006. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24:274-280. (Pubitemid 43853075)
28. Solensky, R. 2006. Drug hypersensitivity. Med. Clin. N. Am. 90:233-260.
29. Sominanda, A., J. Hillert, and A. Fogdell-Hahn. 2007. Neutralising antibodies against interferon beta: persistence is titre dependent. J. Neurol. 254:45.
30. Torres, M. J., C. Mayorga, and M. Blanca. 2009. Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J. Investig. Allergol. Clin. Immunol. 19:80-90.
31. Torres, M. K., D. C. Draghi, C. M. Pillar, N. P. Brown, D. F. Sahm, D. Sandvang, and H. H. Kristensen. 2008. Activity of NZ2114 against staphylococcal and streptococcal isolates, including resistant phenotypes, abstr. F1-3962. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
32. Von Drygalski, A., B. R. Curtis, D. W. Bougie, J. G. McFarland, S. Ahl, I. Limbu, K. R. Baker, and R. H. Aster. 2007. Vancomycin-induced immune thrombocytopenia. N. Engl. J. Med. 356:904-910.
33. Wierda, D., H. W. Smith, and C. M. Zwickl. 2001. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158:71-74.